FDA Approves Tecentriq Plus Chemotherapy for Initial NSCLC Treatment

[LUNGevityKristin]

From the article, “We are pleased to offer this Tecentriq-based combination as a new treatment option that can provide a clinically meaningful survival benefit for people with non-squamous non-small cell lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Today’s approval offers another opportunity to help prolong the lives of people with this type of the disease'.”

You can read the full story here:  https://www.gene.com/media/press-releases/14827/2019-12-03/fda-approves-genentechs-tecentriq-plus-c